Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

GE Healthcare: New software supports screening, confirmation and characterization of anti-drug antibodies
November 2008
SHARING OPTIONS:

GE Healthcare introduces a new immunogenicity software package for its Biacore T100 label-free protein interaction analysis system, to support screening, confirmation and characterization of anti-drug antibodies during preclinical and clinical development. Biacore T100 Immunogenicity Package addresses the problem of drug interference by enabling measurement of anti-drug antibodies in the presence of excess amounts of drug. The package also includes guidelines and recommendations for development of immunogenicity assays, leading to reduced assay development time. Screening of anti-drug antibodies with Biacore instruments can detect early immune responses, which are characterized by antibodies with low affinity and that interact with the drug with rapid kinetics. Tools provided by Biacore T100 Immunogenicity Package also allow for easy confirmation of positive samples and elimination of false positives through drug depletion. Comprehensive characterization of immune response by determination of antibody isotype and anti-drug antibody binding stability can be achieved using dedicated software tools included in Biacore T100 Immunogenicity Package.

 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.